Fierce Pharma
FEBRUARY 1, 2024
Even after the acquisitions of Prometheus and Acceleron, Merck is ready to make more deals in the $1 to $15 billion range, according to CEO Rob Davis.
MedCity News
FEBRUARY 1, 2024
Despite Cigna and Humana ditching their pursuits to combine in December, one industry expert believes there’s still a chance after Cigna announced its plan to sell its Medicare Advantage business to Health Care Service Corp.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Fierce Pharma
FEBRUARY 1, 2024
With Merck reporting a whopping $25 billion sales haul for | With Merck reporting a whopping $25 billion sales haul for Keytruda on Thursday, the PD-1 cancer superstar appears to be the world’s top-selling drug in 2023. Keytruda looks set to take over the top spot from Pfizer and BioNTech’s Comirnaty, which ruled the previous two years, scoring sales of $55.9 billion in 2022 and $55.1 billion in 2021.
MedCity News
FEBRUARY 1, 2024
To meet evolving consumer expectations, providers must have a strong digital marketing strategy and user experience online. Here are 5 healthcare marketing trends to pay attention to in 2024.
Advertisement
What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.
Fierce Pharma
FEBRUARY 1, 2024
As Sanofi strives to become a global immunology leader, it's also busy making the most of a crucial respiratory launch with partner AstraZeneca. | As Sanofi strives to become a global immunology leader, it's also busy making the most of a crucial respiratory launch with partner AstraZeneca. On both fronts, Sanofi expects to see dividends in 2024.
PharmaTimes
FEBRUARY 1, 2024
Tumours with high mtDNA mutations more likely to respond to Opdivo
Pharma Rep Focus brings together the best content for pharma rep professionals from the widest variety of industry thought leaders.
MedCity News
FEBRUARY 1, 2024
Protagonist Therapeutics’ rusfertide could have preliminary data next year from its Phase 3 test in polycythemia vera. If the peptide drug wins FDA approval in this rare blood disorder, the partners will share in U.S. commercialization while Takeda is responsible for the drug in the rest of the world.
Fierce Pharma
FEBRUARY 1, 2024
Despite litigation and denouncements from the biopharma industry, Medicare price negotiations under the Inflation Reduction Act are rolling on. | Despite litigation and denouncements from the biopharma industry, Medicare price negotiations under the Inflation Reduction Act are rolling on. And today, the government is sending out its first round of offers on affected drugs.
pharmaphorum
FEBRUARY 1, 2024
Almirall has formed a three-year alliance with Microsoft designed to accelerate the discovery and development of personalised dermatology therapies.
Fierce Pharma
FEBRUARY 1, 2024
As Roche CEO Thomas Schinecker sees it, the Swiss pharma made a “major achievement” in 2023. Despite a sharp decline in COVID-related sales, the company was able to grow overall revenues | As Roche CEO Thomas Schinecker sees it, the Swiss pharma made a “major achievement” in 2023. Despite a sharp decline in COVID-related sales, the company was able to grow overall revenues thanks in large part to the performance of eye disease drug Vabysmo.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
pharmaphorum
FEBRUARY 1, 2024
A phase 2 trial of Lundbeck’s alpha-synuclein-targeting drug Lu AF82422 has failed to reach statistical significance in patients with multiple system atrophy (MSA), although the company says there are encouraging “signals of efficacy” in the data.
Fierce Pharma
FEBRUARY 1, 2024
Despite the recent loss of exclusivity on Takeda's ADH | As Vyvanse generics take a chunk out of Takeda's sales, the company is hopeful its roster of new drugs, including its dengue fever vaccine Qdenga, can keep revenues intact.
pharmaphorum
FEBRUARY 1, 2024
A single dose of a gene-editing drug being developed by Intellia Therapeutics almost eliminated attacks in patients with hereditary angioedema (HAE) in a clinical trial, pointing to the potential of CRISPR-based drugs delivered in vivo to treat diseases.
Fierce Pharma
FEBRUARY 1, 2024
Cultivating Connections: Continuity in Patient Engagement | 4 Ways to Bring Greater Precision to Oncology Omnichannel Experiences
Advertisement
Every marketer knows how important it is to prove their efforts drive sales opportunities, but that’s easier said than done. When problems like sales and marketing misalignment, lack of data, and wasted efforts persist, marketers can’t measure, prove, or increase their impact on revenue at a time when demonstrating marketing value is critical. Using analyst and expert data, this guide to marketing impact and content attribution explains: How B2B buyers use content The most common types of conten
MedCity News
FEBRUARY 1, 2024
Coordination of benefits is a critical pillar of the Medicaid program as it ensures the efficient use of resources, prevents overutilization, promotes equity in resource distribution, mitigates fraud and abuse, contributes to program longevity and ultimately enhances healthcare access for beneficiaries.
Fierce Pharma
FEBRUARY 1, 2024
“We have a vision, which is to close the gap between scientific knowledge and clinical practice.” | Experienced healthcare communications expert and MD of MedThink Communications John Kane discusses the importance of physician knowledge of the patient’s psychosocial status on treatment plans and outcomes.
MedCity News
FEBRUARY 1, 2024
There’s a common belief in the healthcare industry that partnering with Group Purchasing Organizations (GPOs) means that most or all non-clinical purchases are covered by the contract. It almost sounds too good to be true: GPOs have all the answers for all your procurement needs. Finally, a one-stop shop for all your procurement solutions! Unfortunately, this is far from reality.
Fierce Pharma
FEBRUARY 1, 2024
Takeda paid $300 million upfront to license a blood disorder candidate. Lonza will close a biologics plant in China. A U.S. draft bill targets several Chinese biotech companies. And more. | Takeda paid $300 million upfront to license a blood disorder candidate. Lonza will close a biologics plant in China. A U.S. draft bill targets several Chinese biotech companies.
MedCity News
FEBRUARY 1, 2024
Prior authorization software startup Cohere Health raised $50 million on Thursday, bringing its total funding to $106 million. The need for software to streamline the prior authorization process is perhaps more evident than ever given CMS’ new rule on the matter.
PharmaTimes
FEBRUARY 1, 2024
Prescriptions ordered via the app are expected to save around 1.
MedCity News
FEBRUARY 1, 2024
The more pharma companies do to become service providers in the personalized medicine era, the more they’ll succeed and the more lives they’ll help to save.
Pharmaceutical Technology
FEBRUARY 1, 2024
Merck & Co (MSD) has reported a 1% revenue increase from 2022, and may face setbacks in the next few years from top-selling drugs.
Advertisement
Quotas need to be hit. Revenue goals need to be met. This reality makes shortening sales onboarding time a top priority. Organizations with a standard onboarding process boost employee retention by 58% and increase productivity by 50%. Unfortunately, many companies struggle with inefficient processes that lead to high turnover and missed revenue opportunities.
pharmaphorum
FEBRUARY 1, 2024
Takeda licenses late-stage polycythemia vera drug candidate rusfertide from Protagonist Therapeutics, adding to its rare blood disorder pipeline.
Integrity Solutions
FEBRUARY 1, 2024
Is sales still a viable profession today? Is it something needed or that people even want to do? Many who are currently in sales positions or are considering a role in sales are beginning to question what the job really means today and whether it’s one they can be proud of — especially when it feels like their whole purpose can feel like it’s to pressure or coerce buyers into doing something.
Copyright Clearance Center
FEBRUARY 1, 2024
February 1, 20 24 – Danvers, Mass. – CCC , a leader in advancing copyright, accelerating knowledge, and powering innovation, announces that its President and CEO, Tracey Armstrong , was named a winner of the 2024 BIG Innovation Award recognizing organizations, products, and people bringing new ideas to life in innovative ways and presented by Business Intelligence Group.
Pharmaceutical Technology
FEBRUARY 1, 2024
Novartis has announced net income soaring by 62% to $8.6bn for the full year 2023 (FY 2023) from the previous year’s $6.04bn.
European Pharmaceutical Review
FEBRUARY 1, 2024
The National Institute for Health and Care Excellence (NICE) has recommended AbbVie’s Tepkinly ® (epcoritamab) as the first injectable bispecific antibody for certain adults with the blood cancer diffuse large B-cell lymphoma (DLBCL). Epcoritamab is indicated as an additional administration option for DLBCL, in adults whose cancer has relapsed or been refractory after two or more lines of systemic therapy.
Copyright Clearance Center
FEBRUARY 1, 2024
Legislation often lags technological advances. The EU's Digital Single Market Copyright Directive leaves many open questions regarding AI text- and data-mining.
European Pharmaceutical Review
FEBRUARY 1, 2024
Positive results from the first global study for chimeric antigen receptor (CAR)-antologous T cell (BCMA CAR T) injection (Equecabtagene Autoleucel) in immune-mediated necrotising myopathy (IMNM), suggest that the cell therapy could provide a new therapeutic option for antibody-mediated autoimmune disorders. the cell therapy could provide a new therapeutic option for antibody-mediated autoimmune disorders” IMNM is an autoimmune-mediated skeletal muscle disorder belonging to an idiopathic i
Impetus Digital
FEBRUARY 1, 2024
Register for one of Impetus’ upcoming webinars between February 26-28: Top-5 Trends in Virtual KOL Engagement About the webinar We’re taking a look at the top trends from 2023 and share our predictions for the new year. Our expert speakers will share their unique industry insights and the “best of the best” virtual collaboration and insight-gathering programs from 2023.
Advertisement
Are your sellers unsure about using AI in their day-to-day workflows? Or are they eager to try but uncertain where to start? They might be asking: Which tasks are best suited for AI? How will using AI affect my relationship with my customers? With so many tools available, which ones are the most useful to me? To help answer these and other common questions about using AI during the sales cycle, we surveyed B2B sellers who were early adopters to get their insight and advice about how to use gen A
Expert insights. Personalized for you.
321 
Let's personalize your content